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Aims and objectives: Helicobacter pylori has been classified as high priority pathogen by
the WHO in 2017. The emergence of antibiotic-resistant strains is one of the main causes of
treatment failure in H. pylori infection. This study determined and characterized primary and
secondary resistances in H. pylori in Malaysia.
Materials and methods: Gastric biopsies from antrum (n=288) and corpus (n=283) were
obtained from 288 patients who underwent endoscopy at Universiti Kebangsaan Malaysia
Medical Center (UKMMC), Kuala Lumpur, Malaysia. Antibiotic susceptibility to six classes
of antibiotics was determined by the E-test. Mutations conferring in resistance in functional
genes were identified by PCR and sequencing.
Results: Overall resistance rates to metronidazole, clarithromycin and levofloxacin were
59.3% (35/59), 35.6% (21/59) and 25.4% (15/59), respectively. Secondary isolates showed
significantly higher resistance rates to clarithromycin compared to the primary isolates.
Mixed infection with susceptible and resistant isolates was observed in 16.2% (6/37) of
cases, of which 83.3% (n=5) had infection with the same strain. 41% (18/44) of isolates were
resistant to more than one class of antibiotics of which 50% (9/18) were multidrug-resistant,
two being primary and seven being secondary isolates. Mutations in rdxA, 23S rRNA and
gyrA genes were associated with resistance to metronidazole, clarithromycin and levoflox-
acin, respectively.
Conclusion: The high level of resistance to metronidazole, clarithromycin and levofloxacin
seen in H. pylori isolates in our setting warrants the need for continuous surveillance and
highlights caution in use of antibiotics generally used as first-line therapy in H. pylori
eradication regimen.
Keywords: Helicobacter pylori, antibiotic resistance, clarithromycin, metronidazole,
levofloxacin, point mutation
Introduction
Helicobacter pylori is one of the most prevalent global pathogens that colonizes an
estimated 50% of the world’s population.1 The precise epidemiology of H. pylori
infection still remains unclear; although various risk factors including lower socio-
economic status, infected parents, contaminated water sources, smoking, ethnicities
and geographic location may increase the risk ofH. pylori infection.2 Person-to-person
transmission by oral-oral, fecal-oral or gastro-oral exposure is suggested to be the most
likely route of transmission.3 The evidence that H. pylori infection causes peptic ulcer
disease is compelling hence all consensus guidelines recommend eradication of H.
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pylori for patients with symptoms.4 Standard triple therapy
uses a combination of a proton pump inhibitor and two
antibiotics, either clarithromycin and amoxicillin or metro-
nidazole for a period of 7–14 days.5 However, this therapy
has been questioned because of the increased eradication
failure rates.6 Many factors have been implicated as causes
of treatment failure, including ineffective penetration of anti-
biotics into the gastric mucosa, antibiotic inactivation by the
low stomach pH, a lack of patient compliance, and the
emergence of acquired resistance to antibiotics by H. pylori.
The effectiveness of “legacy triple therapy” recommended
byMaastricht III Consensus Report provides disappointingly
low treatment success (i.e., below 80%).7
Antibiotic resistance in H. pylori strains has been shown
to be the main factor causing eradication failure or low
eradication rate in treated patients.8 The mechanisms of
antibiotic resistance in H. pylori is mainly due to genetic
mutations. For example, resistance to clarithromycin in H.
pylori is due to point mutations in the peptidyltransferase
region of domain V of the 23S rRNA. The most common
mutation is an A-to-G transition at position 2143 (A2143G)9
but several other point mutations, at positions A2142G,
A2144G, and T2182C, have also been described.10,11
Reports have indicated that other mutations, such as
A2115G, G2141A, C2147G, T2190C, C2195T, A2223G,
and C2694A, might also be associated with clarithromycin
resistance.12,13 Metronidazole resistance in H. pylori is com-
plex and is primarily associated with mutations in rdxA and
frxA14 which is often a result of frameshift mutation, inser-
tions and deletions. Resistance to fluoroquinolones arises
from mutations in the quinolones resistance-determining
region (QRDR) of gyrA.15 Amoxicillin resistance has been
associated with amino acid substitutions (D535N, S543R and
T556S) found in penicillin-binding protein 1.16 The resis-
tance to tetracycline is due to mutations in the 16S rRNA,
where single or double base-pair substitutions (A928C,
AG926-927→GT and A926G/A928C) as well as triple sub-
stitution (AGA926–928→TTC) confer low to high-level
tetracycline resistance in H. pylori.17 Resistance to rifampi-
cin is due to the presence of mutations in RNA polymerase
subunit B gene, rpoB.18
There is an increasing trend in primary resistance
among H. pylori worldwide with guidelines recommend-
ing H. pylori culture and susceptibility testing following
two unsuccessful courses of treatment.5 Antibiotic suscept-
ibility testing is unavailable in most of the diagnostic
laboratories and so epidemiological data on secondary
resistance in H. pylori is essential in allowing the rational
use of antibiotics following several failures in treatment.19
In this manner, the treatment success of a particular anti-
biotic regimen can be reliably predicted based on epide-
miological data, even in the absence of individualized H.
pylori culture and susceptibility testing. The aims of this
study were to determine antimicrobial resistance mechan-
isms in primary and secondary isolates of H. pylori by
identifying the mutations associated with antibiotic-resis-
tance phenotypes in H. pylori isolated from patients with
dyspepsia in Kuala Lumpur, Malaysia by presenting both
phenotypic and genotypic data.
Materials and methods
This study was approved by the Medical Research Ethic
Committee of the University (UKM 1.5.3.5/244/ETP-
2013-042) and written informed consent was obtained
from each patient. The study was conducted in accordance
with the Declaration of Helsinki.
Patient sampling
A total of 288 consecutive patients consisting of 129
Malays, 110 Chinese, 29 Indians and 20 from other ethnic
background with chronic dyspepsia undergoing oesophago-
gastroduodenoscopy (OGDS) at the Universiti Kebangsaan
Malaysia Medical Center (UKMMC), Kuala Lumpur,
Malaysia from April 2014 to August 2015 were enrolled
in the study. Patients who had history of eradication failure
and those that did not take antibiotics for at least 4 weeks
prior to the time of enrollment were included in the study.
Patients’ age was between 18 and 89 years with the mean
age of 52.41±16.44 years and median age of 55. For each
patient, three biopsies were obtained from the antrum and
corpus of the stomach, each placed in different tubes for
culture, rapid urease test and histopathological examination.
H. pylori culture
Biopsies for culture were placed in Brucella broth (BBL;
Becton Dickson, USA) containing 15% glycerol and trans-
ported to the Microbiology laboratory in UKMMC.
Gastric biopsies were plated onto Columbia agar (Oxoid,
Basingstoke, UK) supplemented with 7% defibrinated
sheep blood (Oxoid) and Dent’s supplement (Oxoid). The
inoculated agar plates were incubated at 37°C up to 5–10
days in microaerophilic conditions generated using micro-
aerophilic CampyGen gas pack (Oxoid). Culture was
recorded as positive when H. pylori growth identified by
Gram staining showed gram-negative curved/spiral rods
and positive for urease, catalase and oxidase tests.20
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Colonies were subcultured on several agar plates and used
for antibiotic susceptibility testing and DNA extraction.
Rapid urease test
Biopsies were immersed in urease medium and a color
change was recorded between 10 mins and 24 hrs because
of hydrolysis of urea into carbon dioxide and ammonia by
urease-producing Helicobacter strains. The ammonium ion
increases the pH of the medium, which was detected by
the indicator phenol red, resulting in color change from
yellow to reddish pink.
Histopathological examination
Biopsies for histopathological examination were fixed in
10% formalin and transported to the Pathology Laboratory
in UKMMC. Paraffin-embedded section of the biopsies
was prepared, cut and stained with Warthin-Starry staining
for detection of H. pylori.
Antibiotic susceptibility testing
Due to strain fastidiousness, Clinical Laboratory
Standard Institute (CLSI) recommended guidelines for
antibiotic resistance in H. pylori by determination of the
minimum inhibitory concentration (MIC) to different
classes of antibiotics, as there are no standardized disc
diffusion methods defined for testing in H. pylori sus-
ceptibility. The MIC of H. pylori isolates was deter-
mined to six classes of antibiotics (metronidazole,
clarithromycin, amoxicillin, levofloxacin, tetracycline
and rifampicin) by E-test. Bacterial suspension equiva-
lent to McFarland 3.0 standard (approximately 107 cfu/
mL) was prepared from a pure culture of H. pylori. Two
hundred microliter of bacterial suspension were dis-
pensed using sterile tip onto Muller-Hinton agar with
5% sheep blood and streaked in 3 different directions
using sterile swab such that it produced confluent
growth. The E-test strips (bioMérieux, Marcy-l’Etoile,
France) were placed on each plate and the plates were
incubated in a microaerophilic environment at 37°C for
72 hrs. Resistance breakpoint for metronidazole was >8
mg/L,21 amoxicillin,22 levofloxacin,23 tetracycline24
were >1 mg/L and for rifampicin >4 mg/L.25 The epi-
demiological cut off for clarithromycin was defined as
≤0.25 mg/L (susceptible), 0.5 mg/L (intermediate), ≥1
mg/mL for resistant according to CLSI guidelines.26 H.
pylori strain ATCC 43526 was included as a control.
The MIC50 and MIC90 of antibiotics for primary and
secondary H. pylori isolates were calculated for each
antibiotic.
DNA extraction, PCR and sequencing
H. pylori pure cultures on Columbia blood agar were
scraped off and suspended in phosphate-buffered saline.
The DNA was extracted using FavorPrep™ Tissue
Genomic DNA Extraction Mini kit according to the man-
ufacturer’s instructions (Favorgen Biotech Corporation,
Ping-Tung, Taiwan). The extracted DNA was stored at
−20°C until further use.
Mutations in rdxA, frxA, 23S rRNA and gyrA genes
were determined by targeted gene sequencing approach
as described earlier.27–29 The amplification conditions
consisted of an initial denaturation at 95 °C for 3 mins,
followed by 30 cycles of denaturation at 95°C for 30 s;
annealing at 60°C (for rdxA) or 55°C (for frxA) or 54°C
(for 23S rRNA) or 50°C (for gyrA) for 30 s and exten-
sion at 72°C for 1 min with final extension at 72°C for
10 mins. The PCR amplification was performed in a PCR
Thermal Cycler machine (iCycler; Bio-Rad Laboratories,
Hercules,CA, USA). The amplified products were puri-
fied using Geneaid PCR cleanup kit (Geneaid, New
Taipei City, Taiwan) and sequenced using a BigDye
terminator v3.1 sequencing kit on ABI 3730×L sequencer
(MyTACG Bioscience Enterprise, Selangor, Malaysia).
Comparative sequence analyses between resistant and
susceptible strains were carried out using BioEdit
software (http://www.mbio.ncsu.edu/bioedit/bioedit.html).
The DNA sequence results were aligned and compared
to the wild-type isolates of H. pylori 23S rRNA
(Accession no. KC556778), H. pylori 128A rdxA
(Accession no. AF180396) and H. pylori gyrase A sub-
unit (gyrA) (Accession no. L29481).
RAPD-PCR fingerprinting
In patients with a discordant antibiotic susceptibility pattern
between the isolates from the antrum and corpus of the sto-
mach, DNA fingerprinting via random amplified polymorphic
DNA analyses (RAPD-PCR) was performed using primers
1254, 1281 and 1284 as described by earlier30 in order to find
out whether these patients were infected with different or same
strains. PCR was carried out in 25 μL volumes containing 20
ng of genomicDNA, 3mMMgCl2, 400 μMof each dNTP, 0.8
µM of primer and 0.1 U/µL of EconoTaq® DNA polymerase
(Lucigen®, Middleton, WI, USA) in the buffer provided.
T100™ Thermal Cycler (Bio-Rad Laboratories) was used
for amplification and the cycling program was denaturation
Dovepress Hanafiah et al
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at 94°C for 1 mins, followed by 45 cycles of 36°C for 1 min,
72°C for 1 min; and a final extension at 72°C for 10 mins. The
PCR products were analyzed by electrophoresis in a 2%
agarose gel while using 0.5× TBE buffer under a lower voltage
(75 V, 2.5 hrs). Gels were stained with GelStain
(Transbionovo, Beijing, China) and photographed under UV
light under a transilluminator (Alphaimager® Hp; Cell
Bioscience).
Statistical analysis
Statistical analysis was performed using SPSS software ver-
sion 23 (SPSS Inc, Chicago, IL, USA). Differences between
groups were statistically evaluated using Chi-square (χ2) test
and Fisher’s exact test with a 95% CI was used to define
differences in the proportion. Differences were considered
significant when P-value was <0.05.
Results
H. pylori infection status and overall
susceptibility profile
A patient was regarded as H. pylori positive when culture
or histology or rapid urease test and histology showed a
positive result. Two hundred and forty-one (83.7%)
patients had not undergone any therapy for H. pylori
infection, whereas 47 (16.3%) patients had previous his-
tory of eradication failure. The frequency of H. pylori
infection observed either by culture or histology or rapid
urease test was 16.7% (48/288). H. pylori infection was
significantly higher in patients with previous treatment
failure (34%, 16/47) compared to untreated patients
(13.3%, 32/241) (χ2=12.21, P=0.0001, OR=3.371, 95%
CI=1.659–6.848). H. pylori infection was detected in
8.5% Malays (11/129), 20.9% Chinese (23/110), 27.6%
Indians (8/29) and 30% other ethnicities (6/20). Among
H. pylori-infected patients, 70.8% (34/48) had infection in
both antrum and corpus, 18.8% (9/48) had infection only
in antrum and 10.4% (5/48) had infection only in corpus.
A total of 59 H. pylori were isolated from 37 H. pylori-
infected patients. Twenty-two patients had H. pylori iso-
lated from both antrum and corpus, 8 from antrum and 7
from corpus. H. pylori were not isolated from 11 infected-
patients positive for rapid urease test and/or histology.
Overall susceptibility profile of H. pylori to the tested
antibiotics, regardless type of isolate (primary or second-
ary) and site of biopsy (antrum or corpus) showed that all
isolates were susceptible to amoxicillin, tetracycline and
rifampicin. Resistance to metronidazole, clarithromycin
and levofloxacin were observed in 59.3% (35/59), 35.6%
(21/59) and 25.4% (15/59) of the isolates, respectively.
Fifteen isolates (25.4%) were susceptible to all tested
antibiotics. Among the 37 patients, 73% (n=27) were
infected with resistant H. pylori strains. Single, dual and
triple H. pylori resistant infection were observed in 43.2%
(16/37), 16.2% (6/37) and 13.5% (5/37) of the patients,
respectively.
Mixed infection
Mixed infection by susceptible and resistant H. pylori
strains was observed in 16.2% (6/37) of the patients
where infection by metronidazole-susceptible and -resis-
tant identified in four patients, clarithromycin-susceptible
and-resistant in one patient and levofloxacin-susceptible
and -resistant in one patient. RAPD DNA fingerprinting
analysis showed that H. pylori strains from antrum and
corpus in one patient had different DNA patterns suggest-
ing a mixed infection in this patient. In the other five
patients, no substantial differences of DNA pattern
between antrum and corpus isolates suggesting an infec-
tion with a single clone of H. pylori strain.
Antibiotic susceptibility profiles of
primary and secondary H. pylori isolates
Primary isolate is defined as H. pylori strain isolated from
patient untreated for Helicobacter infection, whereas sec-
ondary isolate originates from patients with eradication
failure. Among the 59 isolates, resistance to metronida-
zole, clarithromycin and levofloxacin were observed in
56.1% (23/41), 12.2% (5/41) and 17.1% (7/41) of the
primary isolates and 66.7% (12/18), 88.9% (16/18) and
44.4% (8/18) of the secondary isolates. Majority of the
secondary isolates (88.9%) were significantly resistant to
clarithromycin (P=0.0001) compared to the primary iso-
lates (12.2%) (Table 1) and were also resistant to metro-
nidazole and levofloxacin compared to the primary isolates
but the difference was not statistically significant.
Distribution of MICs value of antibiotics
among primary and secondary isolates
Secondary isolates had higher MIC50 values for metroni-
dazole and clarithromycin compared to the primary iso-
lates (Table 1). The MIC50 for levofloxacin showed similar
value for primary and secondary isolates. Secondary H.
pylori isolates show a higher MIC90 for clarithromycin
compared to the primary isolates, whereas for
Hanafiah et al Dovepress
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metronidazole and levofloxacin, the MIC90 were similar
between primary and secondary isolates. For amoxicillin,
tetracycline and rifampicin, a higher MIC90 values were
observed compared to the primary isolates but still in the
susceptible range. Various distributions of MIC values of
the antibiotics were observed among primary and second-
ary H. pylori isolates (Figure S1). For metronidazole, high
MIC value (MIC ≥256 mg/L) was found in 46.3% of the
primary isolates (19/41) and 55.6% (10/18) of the second-
ary isolates. Clarithromycin MIC ≥1 mg/L was detected in
12.2% (5/41) of the primary isolates and 88.9% (16/18)
were detected among the secondary isolates. 17.1% (7/41)
and 44.4% (8/18) of the primary and secondary isolates,
respectively, showed levofloxacin MIC of ≥1 mg/L.
However, a predominance of levofloxacin MIC ≥32 mg/
L was found among the secondary isolates (33.3%; 6/18)
compared to the primary isolates (12.2%; 5/41).
Multi-drug resistance
Among metronidazole, clarithromycin and levofloxacin-
resistant isolates from both primary and secondary cases
(n=44), 59.1% (26/44) were resistant to one antibiotic,
20.5% (9/44) were resistant to two antibiotics, and 20.5%
(9/44) were resistant to all three antibiotics. 7.4% (2/27) of
the primary isolates were multi-drug resistant compared to
41.1% (7/17) of the secondary isolates.
Mutations in rdxA, frxA, 23S rRNA and
gyrA genes
Amino acid substitutions/deletion were identified in 41 sites
of the RdxA protein among 59 H. pylori isolates which
result in 50 different mutations. Among the metronidazole-
resistant strains (Table 2), 40% (14/35) of the strains had
missense mutations, 5.7% (2/35) had a codon deletion and
54.3% (19/35) had frameshift/nonsense mutations. In
addition, frameshift and nonsense mutations were identified
only in metronidazole-resistant strains. As the majority of
the isolates had high-level of metronidazole resistance (MIC
of 32 to >256 mg/L), no association between type of muta-
tion and MIC value was observed. The rdxA alleles of
metronidazole-susceptible strains showed that six isolates
(25%) did not harbor any specific mutations, 8.3% (2/24)
had a codon deletion and 66.7% (16/24) had missense
mutations. Screening for the mutation in frxA in 14 metro-
nidazole-resistant isolates demonstrated that 50% (n=7) of
the isolates had frameshift or nonsense mutations, whereas
the rest except one isolate (ETP-26C) harbored at least 3
missense mutations (Table 2).
23S rRNA V domain (nucleotide position at 1995 to
2274) was sequenced in all 59 H. pylori strains. There were
three-point mutations, which included single nucleotide tran-
sition at A2142G, A2143G and T2182G (Table S1).
Mutations at nucleotide position 2142 and 2143 that confer
A to G change were identified in resistant strains only with
majority of the strains had A2143G (90.5%) and only two
strains had A2142Gmutation (Table 3). None of these strains
were found to have double mutations of A2142G and
A2143G but either of these mutations occurred in all resistant
strains. A point mutation at position 2182 from T to C were
identified in both clarithromycin-susceptible (89.5%; 34/38)
and -resistant strains (100%; 21/21). Four clarithromycin-
susceptible isolates had no mutation in 23S rRNA gene.
Among the clarithromycin-resistant strains harboring
A2143G mutation, 8 of 19 (42.1%) strains had high MIC
value (64 to >256 mg/L) (Table 3). The other 11 strains have
various MIC values ranging from 2 to 16 mg/L. Two strains
harbored A2142G mutation in 23S rRNA had MIC value for
clarithromycin of 32 and >256 mg/L each.
QRDR of gyrA (nucleotide at position 32–600) of H.
pylori isolates were sequenced. Upon putative translation,
Table 1 MIC50 and MIC90 of antibiotics for primary and secondary H. pylori isolates
Antibiotic Primary isolates (n=41) Secondary isolates (n=18) OR (95% CI)
MIC50 (mg/L) MIC90 (mg/L) % R (n) MIC50 (mg/L) MIC90 (mg/L) % R (n)
Metronidazole 64 ≥256 a56.1 (23) ≥256 ≥256 a66.7 (12) 1.565 (0.492–4.983)
Clarithromycin ≤0.016 8 b12.2 (5) 8 ≥256 b88.9 (16) 57.6 (10.09–328.94)
Levofloxacin 0.064 ≥32 c17.1 (7) 0.064 ≥32 c44.4 (8) 3.886 (1.13–13.36)
Amoxicillin ≤0.016 ≤0.016 0 ≤0.016 0.125 0
Tetracycline 0.064 0.125 0 0.064 0.25 0
Rifampicin 0.125 0.75 0 0.125 1.5 0
Notes: aPearson Chi-Square; χ2=0.579, P=0.447; bPearson Chi-Square, χ2=32.094, P=0.0001; cFisher’s Exact test, P=0.049.
Abbreviations: R, resistance; MIC, minimum inhibitory concentration.
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four different amino acid variants, in gyrase A subunit at
amino acid position 87 [N87I, N87K] and position 91
[D91N, D91Y] were detected to be exclusively present in
resistant strains only (Table S1). Ten of 15 levofloxacin-
resistant strains exhibited amino acid substitution at position
Asn-87 (66.7%), whereas substitution at positionAsp-91 was
present in 5 other strains (33.3%). For levofloxacin-resistant
isolates, strains harboring mutations N87K, N87I and D91N
had higher MIC values of levofloxacin compared to the
strains harboring mutation D91Y (Table 3).
Discussion
Over the last decades, studies showed decreasing preva-
lence of H. pylori infection worldwide.31 This is also noted
in the present study, where we observed a lower preva-
lence rate of H. pylori infection (16.7%) compared to our
previous study (30.8%).32 Since Malaysia is a multiracial
country with Indian population consistently showing the
highest prevalence rate of H. pylori infection and Malay
the least, the proportion of ethnic composition plays an
important role in determining the overall H. pylori infec-
tion in Malaysia.33,34
Infection with antibiotic-resistant H. pylori, poor patient
compliance,35 drug regimens and treatment duration are
important factors which contribute to the treatment failure
and our study shows that 34% of our patients with treatment
failure were infected with resistantH. pylori strains. Although
a decline in H. pylori infection is seen, an increase in rates of
antimicrobial resistance occurs in many parts of the world.36
Results of the present study show that majority of our clinical
isolates were resistant to at least one antibiotic. An overall high
resistance rates observed in this study were due to the inclu-
sion of both primary and secondary resistance.
Metronidazole is an antimicrobial agent widely used to
treat patients with parasitic infection, periodontal and gyne-
cological diseases in many developing countries.5 This may
explain the high rates of primary resistance to metronida-
zole among H. pylori strains.36 In this study, a total of
59.3% of strains were resistant to metronidazole. Primary
and secondary resistance was reasonably high and
accounted for 56.1% and 66.7% of the isolates, respectively.
Previous studies in Malaysia also reported high rates of
primary resistance in H. pylori toward metronidazole
(32.3–37.4%).37,38 We observed an increasing trend of pri-
mary metronidazole resistance in our previous study37 from
37.4% to 56.1%. High prevalence of metronidazole resis-
tance rate has also been reported in other Southeast Asian
countries such as Indonesia (46.8%),5 Vietnam (69.9%),39
Thailand (36%),40 and Singapore (38.4%).41 Moreover,
secondary resistance to metronidazole in the present study
was higher than the primary resistance.
An overall high resistant to clarithromycin was detected
in 35.6% of strains, where the rates of strains with secondary
resistance (88.9%) were significantly higher than strains with
primary resistance (12.2%). Previous studies in Malaysia
reported low primary resistance rates to clarithromycin
(2.1–6.8%).37 A dramatic increase in primary clarithromycin
resistance was seen in our setting from 2.1% (2011 report) to
12.2% (the present study) and is of concern suggesting the
evolution of antibiotic-resistant H. pylori. The rise of clari-
thromycin resistance rate has also been observed in other
local reports.38,42 Clarithromycin is the key antibiotic in the
first-line H. pylori therapy regimen. A significant difference
between primary and secondary resistance to clarithromycin
indicates that infection with clarithromycin-resistant H.
pylori isolates results in the failure of eradication therapy.
Table 3 23S rRNA, gyrA mutations and the range of minimum inhibitory concentration (MIC) values in H. pylori-susceptible and
-resistant isolates
Clarithromycin/23S rDNA Susceptible (n=38), n (%) Resistant (n=21), n (%) MIC value (range; mg/L)
No mutation 4 (10.5) 0 ≤0.016
A2142G 0 2 (9.5) 32–>256
A2143G 0 19 (90.5) 2–>256
Levofloxacin/gyrA Susceptible (n=44), n (%) Resistant (n=15), n (%) MIC value (range; mg/L)
No mutation 44 (100) 0 <0.002–0.19
N87I (Asn87Ile) 0 2 (13.3) >32
N87K (Asn87Lys) 0 8 (53.3) 16–>32
D91N (Asp91Asn) 0 2 (13.3) >32
D91Y (Asp91Tyr) 0 3 (20) 3–12
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Analysis of the clarithromycin MIC distribution shows that
clarithromycin may still be a highly effective drug, but only
in patients infected with susceptible strains.
A higher primary resistance rate of levofloxacin was
found in our study compared to other local reports.37,38
However, the activity of levofloxacin is still high as more
than 80% and 50% of primary and secondary isolates,
respectively, were inhibited at low MIC values.
Increasing trend in levofloxacin resistance worldwide43 is
a major concern as it is recommended for salvage treat-
ment regimens in clarithromycin failed treatments.5
H. pylori isolates in our region is consistently suscepti-
ble to amoxicillin, tetracycline and rifampicin as shown in
the present study and others.37,38 A stable primary resis-
tance to amoxicillin and tetracycline has been reported in
Singapore from 2002 to 2014.41 Even though amoxicillin is
one of the key antibiotics in first-line triple therapy for H.
pylori eradication,5 the finding suggests that exposure to
amoxicillin did not induce the development of resistance.
Awide range of tetracycline and rifampicin MIC values and
the shift in MIC for these drugs toward higher values could
be of concern as both drugs are proposed in third-line
rescue regimen for H. pylori eradication therapy.
Some of our patients (16.2%) were infected with
strains of different antibiotic susceptibilities from the
antrum and corpus. Majority of our patients with discor-
dant antibiotic susceptibility between antrum and corpus
were infected with a single H. pylori strains as shown by
identical RAPD fingerprinting analysis. This suggested
that antibiotic-resistant H. pylori strains develop from a
pre-existing susceptible strain rather than co-infection with
a different strain.44 The presence of heteroresistant strains
in the present study is common45,46 indicating that no
single biopsy site can be considered representative of
antimicrobial susceptibility testing and can lead to under-
estimation of antimicrobial resistance.47 Multiple biopsies
from different sites of the stomach are needed especially in
patients with pangastritis in order to verify the presence of
heteroresistance to antibiotics.47
Multi-drug resistance H. pylori strains have been
reported from many countries.24,39,48,49 Multidrug-resis-
tance in secondary isolates was higher than those in pri-
mary indicating the role of antibiotics in the generation of
resistance in H. pylori.
Many point mutations in rdxA have been reported and
these positions were not uniform and highly distributed
among different H. pylori strains.50 Frameshift and non-
sense mutations contributed to metronidazole resistance as
these mutations were identified only in metronidazole-resis-
tant strains, which is in agreement with previous reports.50
About 45% of our metronidazole-resistant strains harboring
missense mutation and a codon deletion had intact rdxA
reading frames. However, half of these isolates harbored
frameshift or nonsense mutations in frxA. Presence of many
missense mutations in both rdxA and frxA might contribute
to metronidazole resistance in our H. pylori isolates.
More than 40% of our strains harboring A2143G muta-
tion in 23S rRNA gene had high clarithromycin MIC value
suggesting that this mutation is associated with highly
resistant H. pylori strains. A previous study reported the
A2143G mutation has a much stronger impact on clari-
thromycin resistance than the A2142G.51
Asn87Lys mutation in the gyrAwas predominant among
our H. pylori isolates. In other regions such as Europe coun-
tries and Japan, the most common mutation was located at
amino acid 9125,52 suggesting that there may be a geographi-
cal variation in gyrA genotype distribution. Furthermore, we
found that more than half of our levofloxacin-resistant strains
harbored Asn87Lys mutation associated with high MIC
values. Results show that screening of gyrA mutations at
amino acids 87 and 91 could be adequate for detecting
levofloxacin-resistant among our strains.
Conclusion
The difference between high prevalence of H. pylori in
Indian population and low prevalence in Malays in
Malaysia is likely to be environmental in origin strains
remains confined to predefined cohorts which in the case
of Malaysia, is ethnic based supported by distinctness of
strains between different races. The increasing incidence
of H. pylori resistance to metronidazole, clarithromycin
and levofloxacin in Malaysia warrants systematic surveil-
lance to optimize the selection of first-line and second-line
treatment regimens which can be suitable for people of
specific ethnic groups due to their likelihood of being
infected with a lineage-specific strain belonging to ethnic
cohort. This may reduce secondary resistance due to treat-
ment failure and prevent the development of resistance in
H. pylori isolates. It is recommended that antibiotic sus-
ceptibility testing be performed before administration of
the first-line antibiotics to reduce the development of sec-
ondary resistance especially to clarithromycin which is an
effective drug for the treatment of metronidazole-resistant
H. pylori. Rapid point of care assays and/or implementa-
tion of molecular assays for detection of mutations in
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rdxA, frxA, 23S rRNA and gyrA can aid in linking geno-
typic results with the phenotype for treatment of disease.
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